ALS oral therapy slows disease progression in preclinical testing

ALS oral therapy slows disease progression in preclinical testing

M102, an experimental oral therapy designed to simultaneously activate two molecular pathways that protect against nerve cell damage, showed promise in preclinical models of amyotrophic lateral sclerosis (ALS), according to a study. The compound, discovered and developed by researchers at the University of Sheffield’s Institute for Translational Neuroscience (SITraN)…

ALS panel series shares information, insight, and hope

When my late husband, Jeff, was diagnosed with ALS in the fall of 2018, I’d heard of the disease only peripherally. Like many, I’d completed the Ice Bucket Challenge in 2014 without an inkling that someday this disease would affect someone I loved. Swept up in the momentum…

BCI technology may give voice to Mandarin speakers with paralysis

Scientists have developed a brain-computer interface (BCI) capable of instantly translating a person’s thoughts into written Mandarin Chinese. The technology expands the reach of BCIs, devices that capture brain signals to help people communicate, beyond its traditional focus on English speakers. It opens up the potential for millions more people…